Thomas Smith

Q: What is Thomas Smith's success rate?

Thomas Smith currently has a success rate of 85.81449970890516.

Q: What is the average return of Thomas Smith's calls?

Their stock ratings have generated an average return of 26.058575513068355.

Leerink Partners | Healthcare

Thomas Smith is an analyst from Leerink Partners specializing in the Healthcare sector. Ranked #1031 out of 4771 analysts, they have issued 14 stock ratings with a success rate of 85.81% and an average return of 26.06%.

With 14 ratings to date, Thomas Smith is beginning to establish credibility in the Healthcare sector. They have achieved a success rate of 85.81% and an average return of 26.06%, highlighting promising potential as their track record develops further.

#1031

Out of 4771

Total Ratings

+85.81%

Success Rate

+26.06%

Average Return

Recent Ratings Analysis

AVTX

Buy

Jul 06, 2026

Target

$38.00

Current

$17.18

Performance

-13.93%

Thomas Smith rated AVTX as Outperform on Jul 06, 2026, setting a price target of 38. The stock has underperformed, dropping 13.93% despite the bullish target of 38.

MLTX

Buy

Jul 01, 2026

Target

$29.00

Current

$13.18

Performance

-31.10%

On Jul 01, 2026, MLTX was given a Outperform rating by Thomas Smith, with a target price of 29. Despite the Buy call, shares fell from 13.18 to 13.18, challenging the optimistic stance.

ABVX

Buy

Jun 30, 2026

Target

$148.00

Current

$115.95

Performance

-12.99%

ABVX received a Outperform rating from Thomas Smith on Jun 30, 2026, aiming for 148. The rating hasn’t played out as hoped, with the stock trading 12.99% below expectations.

ALT

Buy

Jun 22, 2026

Target

$10.00

Current

$3.29

Performance

12.29%

On Jun 22, 2026, Thomas Smith published a Outperform outlook on ALT, with a target of 10. Shares gained 12.29%, underscoring the accuracy of the bullish outlook toward 10.

SABS

Buy

Jun 15, 2026

Target

$12.00

Current

$3.42

Performance

-12.31%

Thomas Smith on Jun 15, 2026 assigned SABS a Outperform rating, with a price target of 12. The call has struggled to gain traction, with shares losing 12.31%.

XFOR

Buy

Jun 02, 2026

Target

$12.00

Current

$3.40

Performance

—

On Jun 02, 2026, Thomas Smith reaffirmed XFOR with a Outperform rating, targeting 12. Market indecision has kept the 12 target in a holding pattern.

EQ

Buy

May 28, 2026

Target

$6.00

Current

$2.42

Performance

-14.79%

EQ was rated Outperform by Thomas Smith on May 28, 2026, with a price objective of 6. This case shows how bullish projections can fail, with the stock now below 2.42.

SYRE

Buy

Apr 13, 2026

Target

$106.00

Current

$88.71

Performance

40.21%

On Apr 13, 2026, Thomas Smith initiated coverage on SYRE with a Outperform rating and target of 106. The stock’s climb of 40.21% since the call highlights the foresight in the rating.

AGMB

Buy

Mar 03, 2026

Target

$36.00

Current

$13.94

Performance

-12.33%

Thomas Smith issued a Outperform recommendation for AGMB on Mar 03, 2026, price target set at 36. The market hasn’t rewarded the bullish outlook, exposing uncertainty in the call.

RAPT

Hold

Jan 21, 2026

Target

$58.00

Current

$58.01

Performance

0.69%

On Jan 21, 2026, RAPT was evaluated by Thomas Smith, who gave a Market Perform rating and target of 58. Hold sentiment was validated by subdued trading with no breakout beyond 58.005.

IVA

Buy

Jan 12, 2026

Target

$12.00

Current

$4.14

Performance

-24.04%

Thomas Smith rated IVA as Outperform on Jan 12, 2026, setting a price target of 12. The stock has underperformed, dropping 24.04% despite the bullish target of 12.

ALMS

Buy

Jan 07, 2026

Target

$32.00

Current

$9.90

Performance

-44.75%

On Jan 07, 2026, ALMS was given a Outperform rating by Thomas Smith, with a target price of 32. Despite the Buy call, shares fell from 9.9 to 9.9, challenging the optimistic stance.

EVMN

Buy

Dec 01, 2025

Target

$42.00

Current

$10.56

Performance

-49.50%

EVMN received a Outperform rating from Thomas Smith on Dec 01, 2025, aiming for 42. The rating hasn’t played out as hoped, with the stock trading 49.50% below expectations.

QTTB

Hold

Dec 11, 2024

Target

$9.00

Current

$10.72

Performance

80.17%

On Dec 11, 2024, Thomas Smith published a Market Perform outlook on QTTB, with a target of 9. The Hold call missed some of the bullish momentum as shares advanced toward 9.

ACRS

Buy

Nov 19, 2024

Target

$7.00

Current

$5.50

Performance

19.93%

Thomas Smith on Nov 19, 2024 assigned ACRS a Outperform rating, with a price target of 7. The Buy call aligned well with market performance, producing a gain of 19.93%.

Frequency Asked Questions

Who is Thomas Smith?

Thomas Smith is an analyst from Leerink Partners specializing in the Healthcare sector.

What is Thomas Smith's success rate?

Thomas Smith currently has a success rate of +85.81%.

How many ratings has Thomas Smith issued?

Thomas Smith has issued 14 stock ratings so far.

What is the average return of Thomas Smith's calls?

Their stock ratings have generated an average return of +26.06%.

What is Thomas Smith's ranking?

Thomas Smith is ranked #1031 out of 4771 analysts.

What types of ratings does Thomas Smith give?

Their ratings include Buy, Hold, and Sell recommendations, depending on the stock’s outlook.

How can I follow Thomas Smith?

You can follow Thomas Smith by clicking the "Follow Analyst" button on this page to receive updates on their stock calls.

What is the most recent rating by Thomas Smith?

Their latest rating was a Buy on AVTX issued on 2026-07-06.